ADIAL PHARMACEUTICALS INC (ADIL) Stock Overview
USA - NASDAQ:ADIL - US00688A2050 - Common Stock
ADIL Key Statistics, Chart & Performance
The current stock price of ADIL is 0.3605 USD. In the past month the price decreased by -5.43%. In the past year, price decreased by -65.33%.
ADIL Latest News, Press Relases and Analysis
ADIL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52.73 | 805.98B | ||
| JNJ | JOHNSON & JOHNSON | 18.2 | 454.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.59 | 255.92B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.73 | 237.86B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.9 | 222.95B | ||
| MRK | MERCK & CO. INC. | 11.17 | 214.76B | ||
| PFE | PFIZER INC | 7.18 | 138.36B | ||
| SNY | SANOFI-ADR | 11.55 | 124.44B | ||
| GSK | GSK PLC-SPON ADR | 7.68 | 94.55B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.65 | 91.15B | ||
| ZTS | ZOETIS INC | 23.01 | 63.44B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 47.2 | 41.74B |
Related stock screener links
About ADIL
Company Profile
Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Company Info
ADIAL PHARMACEUTICALS INC
1180 Seminole Trail, Suite 495
Charlottesville VIRGINIA 22901 US
CEO: William B. Stilley
Employees: 5
Phone: 14344229800
ADIAL PHARMACEUTICALS INC / ADIL FAQ
What does ADIL do?
Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
What is the stock price of ADIAL PHARMACEUTICALS INC today?
The current stock price of ADIL is 0.3605 USD. The price increased by 2.94% in the last trading session.
Does ADIAL PHARMACEUTICALS INC pay dividends?
ADIL does not pay a dividend.
How is the ChartMill rating for ADIAL PHARMACEUTICALS INC?
ADIL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for ADIAL PHARMACEUTICALS INC?
ADIAL PHARMACEUTICALS INC (ADIL) currently has 5 employees.
Can you provide the market cap for ADIAL PHARMACEUTICALS INC?
ADIAL PHARMACEUTICALS INC (ADIL) has a market capitalization of 7.87M USD. This makes ADIL a Nano Cap stock.
ADIL Technical Analysis
ADIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADIL. While ADIL seems to be doing ok healthwise, there are quite some concerns on its profitability.
ADIL Financial Highlights
Over the last trailing twelve months ADIL reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS increased by 66.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.23% | ||
| ROE | -151.14% | ||
| Debt/Equity | 0 |
ADIL Forecast & Estimates
9 analysts have analysed ADIL and the average price target is 2.55 USD. This implies a price increase of 607.35% is expected in the next year compared to the current price of 0.3605.